Portfolio
Active Investments
Augmedics, Inc. pioneers cutting-edge augmented reality technologies to improve surgical outcomes. The company’s first-of-its-kind, FDA-cleared xvision Spine System® allows surgeons to see patients’ anatomy as if they have “x-ray vision” and accurately navigate instruments and implants during spine procedures.
GT Medical Technologies, Inc. develops and markets GammaTile® Therapy, an FDA-cleared implantable device consisting of bioabsorbable collagen tiles embedded with Cesium-131 radiation seeds to provide immediate, localized radiation therapy following brain tumor resection. This innovative approach enhances clinical outcomes, reduces treatment delays, and improves patient convenience by integrating radiation into the surgical workflow.
Magnolia Medical Technologies, Inc. is a medical device company that develops and manufactures innovative blood and bodily fluid collection devices that significantly improve the accuracy, consistency and predictability of critical in-vitro diagnostic (IVD) tests. Magnolia Medical invented and patented the initial specimen diversion technique (ISDTTM) and device (ISDD®) for blood culture collection and contamination prevention. By mechanically eliminating human errors that cause erroneous test results, the company’s products significantly improve patient safety and reduce hospital costs.
Poseidon Medical, Inc. (formerly Tryton Medical) is a pre-commercial stage private medical technology company focused on developing and commercializing percutaneous implants for the treatment of Left Main lesions. In the US, 20% of patients diagnosed with this life-threatening disease are ineligible for surgery and no interventional option is approved.
Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx, Inc. has focused on developing precision breast cancer tools that will impact a patient’s treatment decision. The company’s DCISionRT test is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit.
Co-founded by PureTech Health (LSE: PRTC), Sonde Health, Inc. is developing a voice-based technology platform to monitor and diagnose psychological and physical medical conditions. The company’s proprietary technology works by sensing and analyzing subtle changes in the voice to create a range of persistent brain, muscle, and respiratory health measurements that provide a more complete picture of health in just seconds. Sonde’s vocal biomarker program has demonstrated the potential to effectively screen and monitor for disease using information obtained from an individual’s voice on commonly-owned devices, and it has the potential to fundamentally change the way mental and physical health is monitored and diagnosed.
Standard Molecular, Inc. is transforming patient care and development of personalized therapies through integrated genomic data. The company’s proprietary platform addresses a key pain point in the rapidly growing use of molecular testing by enabling the exchange of standardized, discrete genomic data to streamline information flow between physician practices and molecular labs.
Exited Investments
AcuFocus, Inc. is a privately held ophthalmic medical device company that develops and markets breakthrough technologies for the improvement of vision. The company’s proven, proprietary technology platform uses a small aperture – or pinhole – effect to allow focused light rays to reach the retina and bring objects into focus. Using this small aperture concept, the IC-8® IOL was designed specifically for patients with cataracts, and it is currently available in select European and Asian markets (not currently approved in the US).
Akili Interactive Labs, Inc. is building clinically validated cognitive therapeutics, assessments, and diagnostics that look and feel like high-quality video games. Leveraging medical-grade science and consumer-grade software technology, the company is seeking to produce a new type of healthcare product that is both highly effective and highly engaging. The company was founded by PureTech, a science and technology research and development company, together with leading neuroscientists and game designers.
Biotheranostics, Inc. is a company focused on helping physicians improve the care of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s Breast Cancer Index® helps oncologists make difficult decisions about extended endocrine therapy for ER+ breast cancer patients based on its ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years. Its CancerTYPE ID® is a validated gene expression test for metastatic patients with diagnostic ambiguity, helping physicians determine optimal site-directed treatment regimens with the goal of improving patient outcomes.
Cardiva Medical, Inc. is a privately held medical device company that is focused on developing and commercializing innovative vascular closure technology. VASCADE® is a new generation extravascular closure device designed to increase the comfort and safety of vascular closure for patients. VASCADE® uses a unique delivery system based on a proprietary collapsible disc technology and a thrombogenic resorbable collagen patch that provide rapid hemostasis while minimizing complications. The company’s latest product is VASCADE MVP®, which is the first vessel closure technology designed specifically for electrophysiology procedures.
Dune Medical Devices was founded in 2002 to realize the medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the ability to detect cancer in real time, this technology holds promise for a broad range of diagnostic and therapeutic applications. The company’s first offering, the MarginProbe® System, is now FDA approved and is being used to deliver real-time assessment on excised tissue in breast cancer surgery. A 300-patient randomized study has shown a reduction in re-operation rates by 56% over the standard of care.
EndoGastric Solutions, Inc. (EGS) is a medical device company focused on developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of gastroesophageal reflux disease (GERD). EGS has combined advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) procedure—a minimally invasive solution that addresses a significant unmet clinical need.
